clinical trial · NCT05979818
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Second Xiangya Hospital of Central South University·phase2·recruiting·n = 118
Non Small Cell Lung CancerPropranololImmune Checkpoint InhibitorsImmunotherapyβ-adrenergic AntagonistsEmotional DistressPD-1 InhibitorsPropranolol hydrochlorideSintilimabChemotherapyPropranolol hydrochloride matching placeboPropranolol Hydrochloride R2PD
brief summary
This study is a prospective multi-center Phase Ib/II clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta-adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.
started
Nov 13, 2024
primary completion
Oct 31, 2028
completion
Dec 31, 2032
last updated
Nov 19, 2026
official title
Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol